磺达肝癸钠和依诺肝素对NSTE-ACS保守治疗老年患者的临床研究

Clinical Study on the Conservative Treatment of NSTE-ACS in Elderly Patients with Sodium Sulfonate and Enoxaparin

摘要: 目的：分析老年NSTE-ACS患者选择保守治疗后应用磺达肝癸钠和依诺肝素治疗的有效性和安全性。方法：选取我院急诊科收治的176名NSTE-ACS选择保守治疗的老年患者作为研究对象，根据患者应用不同的抗凝药物，将其随机分为磺达肝癸钠组(n = 87)和依诺肝素组(n = 89)，观察和比较两组患者在住院期间内主要疗效终点及安全性终点的发生率。结果：比较两组患者主要疗效终点的发生率，差异无统计学意义(P > 0.05)。磺达肝癸钠组轻度出血的发生率低于依诺肝素组(P < 0.05)。严重出血的发生率，两组间差异无统计学意义(P > 0.05)。结论：对于NSTE-ACS选择保守治疗的老年患者，在住院期间内，磺达肝癸钠和依诺肝素具有相当的临床疗效，但是磺达肝癸钠要比伊诺肝素更加安全。

Abstract: Objective: To analyze the efficacy and safety of fondaparinux sodium and enoxaparin in elderly NSTE-ACS patients during conservative treatment. Methods: Selecting 176 elderly patients with NSTE-ACS who chose conservative treatment in our hospital emergency department as the research object, according to the application of different anticoagulant drugs, patients were randomly divided into the fondaparinux sodium group (n = 87) and the enoxaparin group (n = 89). The incidence of primary efficacy and safety endpoints during hospitalization between the two groups was observed and compared. Results: There was no statistically significant difference between the two groups in the incidence of the main therapeutic end points (P > 0.05). The incidence of mild bleeding in the fondaparinux sodium group was lower than that in the enoxaparin group (P < 0.05). There was no significant difference in the incidence of severe bleeding between the two groups (P > 0.05). Conclusion: In elderly patients with conservative treatment of NSTE-ACS, fondaparinux sodium and enoxaparin have significant clinical efficacy during hospitalization, but fondaparinux is safer than enoxaparin.